We are pleased to announce the successful completion of the pilot phase of our state-of-the-art plant cultivation facility. This milestone marks a significant advance in our ability to support clinical trials up to level 2.

Our facility has demonstrated the ability to produce up to 1kg of recombinant protein in a single cultivation run. This is an unprecedented achievement that opens the door to new opportunities in biotechnology research and development. The pilot phase has shown that our facility not only has the capacity, but also the precision and control to deliver consistent, reliable results. This is essential to meet the stringent requirements of clinical trials.

We are proud of what we have achieved and look forward to fully commissioning our facility in the coming months. With the ability to support clinical trials up to level 2, we are confident that we will make a positive impact on healthcare research. This achievement would not have been possible without the dedication and hard work of our team. We would like to take this opportunity to thank them for their tireless efforts and passion. They have demonstrated their willingness to push the boundaries of what is possible and make a real difference in the world.

We look forward to the next phase of our work and are excited about what the future holds. With our state-of-the-art plant breeding facility, we are well positioned to meet tomorrow’s challenges and remain at the forefront of biotech innovation.